Risk factors for mortality in patients with mucormycosis

Brad Spellberg, Dimitrios P. Kontoyiannis, David Fredricks, Michele I Morris, John R. Perfect, Peter V. Chin-Hong, Ashraf S. Ibrahim, Eric P. Brass

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Optimal clinical care and clinical investigation of patients with mucormycosis are limited by absence of controlled trials, and absence of well-defined predictors of mortality or clinical response. The Deferasirox-AmBisome Therapy for mucormycosis (DEFEAT Mucor) study was the first randomized clinical trial conducted on patients with mucormycosis, and demonstrated that adjunctive deferasirox therapy did not improve outcomes of the disease. The current study describes clinical factors from the 20 patients enrolled to identify those associated with 90-day mortality of the 11 (55%) patients who died by day 90. Age, diabetes mellitus, transplant status, or antifungal therapy were not associated with mortality. However, active malignancy or neutropenia at enrollment were associated with increased mortality. Pulmonary infection was linked with lower Kaplan-Meier survival compared to non-pulmonary infection. Higher baseline serum concentrations of iron and ferritin were also associated with mortality. No patient who progressed clinically during the first 14 days of study therapy survived; however, many patients who clinically improved during that time did not survive to 90 days. In contrast, day 30 clinical response was predictive of 90-day survival. These factors may be useful in defining enrollment randomization stratification critieria for future clinical trials, and in supporting clinical care of patients with mucormycosis.

Original languageEnglish
Pages (from-to)611-618
Number of pages8
JournalMedical Mycology
Volume50
Issue number6
DOIs
StatePublished - Aug 1 2012

Fingerprint

Mucormycosis
risk factors
Mortality
therapeutics
clinical trials
neutropenia
randomized clinical trials
patient care
Survival
ferritin
Therapeutics
Ferritins
diabetes mellitus
Random Allocation
Infection
Neutropenia
infection
Patient Care
Diabetes Mellitus
Iron

Keywords

  • Mortality
  • Mucormycosis
  • Randomized controlled trial
  • Risk factors

ASJC Scopus subject areas

  • veterinary(all)
  • Infectious Diseases

Cite this

Spellberg, B., Kontoyiannis, D. P., Fredricks, D., Morris, M. I., Perfect, J. R., Chin-Hong, P. V., ... Brass, E. P. (2012). Risk factors for mortality in patients with mucormycosis. Medical Mycology, 50(6), 611-618. https://doi.org/10.3109/13693786.2012.669502

Risk factors for mortality in patients with mucormycosis. / Spellberg, Brad; Kontoyiannis, Dimitrios P.; Fredricks, David; Morris, Michele I; Perfect, John R.; Chin-Hong, Peter V.; Ibrahim, Ashraf S.; Brass, Eric P.

In: Medical Mycology, Vol. 50, No. 6, 01.08.2012, p. 611-618.

Research output: Contribution to journalArticle

Spellberg, B, Kontoyiannis, DP, Fredricks, D, Morris, MI, Perfect, JR, Chin-Hong, PV, Ibrahim, AS & Brass, EP 2012, 'Risk factors for mortality in patients with mucormycosis', Medical Mycology, vol. 50, no. 6, pp. 611-618. https://doi.org/10.3109/13693786.2012.669502
Spellberg B, Kontoyiannis DP, Fredricks D, Morris MI, Perfect JR, Chin-Hong PV et al. Risk factors for mortality in patients with mucormycosis. Medical Mycology. 2012 Aug 1;50(6):611-618. https://doi.org/10.3109/13693786.2012.669502
Spellberg, Brad ; Kontoyiannis, Dimitrios P. ; Fredricks, David ; Morris, Michele I ; Perfect, John R. ; Chin-Hong, Peter V. ; Ibrahim, Ashraf S. ; Brass, Eric P. / Risk factors for mortality in patients with mucormycosis. In: Medical Mycology. 2012 ; Vol. 50, No. 6. pp. 611-618.
@article{7de027b4fff248a1a4bce43c027ced4a,
title = "Risk factors for mortality in patients with mucormycosis",
abstract = "Optimal clinical care and clinical investigation of patients with mucormycosis are limited by absence of controlled trials, and absence of well-defined predictors of mortality or clinical response. The Deferasirox-AmBisome Therapy for mucormycosis (DEFEAT Mucor) study was the first randomized clinical trial conducted on patients with mucormycosis, and demonstrated that adjunctive deferasirox therapy did not improve outcomes of the disease. The current study describes clinical factors from the 20 patients enrolled to identify those associated with 90-day mortality of the 11 (55{\%}) patients who died by day 90. Age, diabetes mellitus, transplant status, or antifungal therapy were not associated with mortality. However, active malignancy or neutropenia at enrollment were associated with increased mortality. Pulmonary infection was linked with lower Kaplan-Meier survival compared to non-pulmonary infection. Higher baseline serum concentrations of iron and ferritin were also associated with mortality. No patient who progressed clinically during the first 14 days of study therapy survived; however, many patients who clinically improved during that time did not survive to 90 days. In contrast, day 30 clinical response was predictive of 90-day survival. These factors may be useful in defining enrollment randomization stratification critieria for future clinical trials, and in supporting clinical care of patients with mucormycosis.",
keywords = "Mortality, Mucormycosis, Randomized controlled trial, Risk factors",
author = "Brad Spellberg and Kontoyiannis, {Dimitrios P.} and David Fredricks and Morris, {Michele I} and Perfect, {John R.} and Chin-Hong, {Peter V.} and Ibrahim, {Ashraf S.} and Brass, {Eric P.}",
year = "2012",
month = "8",
day = "1",
doi = "10.3109/13693786.2012.669502",
language = "English",
volume = "50",
pages = "611--618",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Risk factors for mortality in patients with mucormycosis

AU - Spellberg, Brad

AU - Kontoyiannis, Dimitrios P.

AU - Fredricks, David

AU - Morris, Michele I

AU - Perfect, John R.

AU - Chin-Hong, Peter V.

AU - Ibrahim, Ashraf S.

AU - Brass, Eric P.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Optimal clinical care and clinical investigation of patients with mucormycosis are limited by absence of controlled trials, and absence of well-defined predictors of mortality or clinical response. The Deferasirox-AmBisome Therapy for mucormycosis (DEFEAT Mucor) study was the first randomized clinical trial conducted on patients with mucormycosis, and demonstrated that adjunctive deferasirox therapy did not improve outcomes of the disease. The current study describes clinical factors from the 20 patients enrolled to identify those associated with 90-day mortality of the 11 (55%) patients who died by day 90. Age, diabetes mellitus, transplant status, or antifungal therapy were not associated with mortality. However, active malignancy or neutropenia at enrollment were associated with increased mortality. Pulmonary infection was linked with lower Kaplan-Meier survival compared to non-pulmonary infection. Higher baseline serum concentrations of iron and ferritin were also associated with mortality. No patient who progressed clinically during the first 14 days of study therapy survived; however, many patients who clinically improved during that time did not survive to 90 days. In contrast, day 30 clinical response was predictive of 90-day survival. These factors may be useful in defining enrollment randomization stratification critieria for future clinical trials, and in supporting clinical care of patients with mucormycosis.

AB - Optimal clinical care and clinical investigation of patients with mucormycosis are limited by absence of controlled trials, and absence of well-defined predictors of mortality or clinical response. The Deferasirox-AmBisome Therapy for mucormycosis (DEFEAT Mucor) study was the first randomized clinical trial conducted on patients with mucormycosis, and demonstrated that adjunctive deferasirox therapy did not improve outcomes of the disease. The current study describes clinical factors from the 20 patients enrolled to identify those associated with 90-day mortality of the 11 (55%) patients who died by day 90. Age, diabetes mellitus, transplant status, or antifungal therapy were not associated with mortality. However, active malignancy or neutropenia at enrollment were associated with increased mortality. Pulmonary infection was linked with lower Kaplan-Meier survival compared to non-pulmonary infection. Higher baseline serum concentrations of iron and ferritin were also associated with mortality. No patient who progressed clinically during the first 14 days of study therapy survived; however, many patients who clinically improved during that time did not survive to 90 days. In contrast, day 30 clinical response was predictive of 90-day survival. These factors may be useful in defining enrollment randomization stratification critieria for future clinical trials, and in supporting clinical care of patients with mucormycosis.

KW - Mortality

KW - Mucormycosis

KW - Randomized controlled trial

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=84863921945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863921945&partnerID=8YFLogxK

U2 - 10.3109/13693786.2012.669502

DO - 10.3109/13693786.2012.669502

M3 - Article

C2 - 22435877

AN - SCOPUS:84863921945

VL - 50

SP - 611

EP - 618

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

IS - 6

ER -